Stereotaxis (STXS) 3.65 $STXS
Stereotaxis to Present New Clinical Evidence, Features of Automated Technologies at Heart Rhythm 2014
GlobeNewswire - Tue May 06, 3:24PM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced several firsts for its eleventh appearance at the annual Heart Rhythm Society (HRS) Scientific Sessions, to be held May 7-10, 2014 in San Francisco, CA. With a central theme of "Efficiency Established; Outcomes Proven; Safety Undoubted," the Company will share new clinical evidence around efficiencies achieved through its Epoch(TM) Solution, showcase a seminal feature of its latest generation user interface and, for the first time, present the value of its Vdrive(TM) Robotic Navigation System to a U.S. audience.
Stereotaxis Reports 2014 First Quarter Financial Results
GlobeNewswire - Tue May 06, 3:24PM CDT
-Records $7 Million in Recurring Revenue, Aided by Sequential Procedure Growth-
Stereotaxis to Report First Quarter 2014 Financial Results on May 6, 2014
GlobeNewswire - Wed Apr 30, 5:42AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 first quarter ended March 31, 2014 on Tuesday, May 6, 2014 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
Stereotaxis Submits 510(k) Application to FDA for Vdrive(TM) with V-Loop(TM) System
GlobeNewswire - Tue Apr 01, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has submitted a 510(k) Premarket Notification with the Food and Drug Administration (FDA) for the Company's Vdrive(TM) Robotic Navigation System with V-Loop(TM) Variable Loop Catheter Manipulator. This submission includes both the single arm system (Vdrive) and the two arm system (Vdrive Duo). If cleared by the FDA, the Vdrive with V-Loop system will be the Company's second Vdrive product to be cleared for use in the U.S. Its Vdrive with V-Sono(TM) Intracardiac Echocardiography Catheter Manipulator received FDA clearance in July 2013 and has been utilized in more than 75 cardiac ablation procedures to date in North America.
Stereotaxis Expands Credit Facility With Silicon Valley Bank to $10 Million
GlobeNewswire - Mon Mar 31, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into an amended credit agreement with Silicon Valley Bank (SVB) that replaces its existing $3 million revolving facility with a $10 million revolving facility scheduled to mature on March 31, 2015.
20.2% Return Seen to Date on SmarTrend Stereotaxis Call (STXS)
Comtex SmarTrend(R) - Tue Mar 04, 5:21PM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 20.24% as of today's recent price of $5.05.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 26, 12:51PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Stereotaxis Signs Distribution Agreement for Niobe(R) Technology in Japan
GlobeNewswire - Tue Feb 25, 3:06PM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into a definitive agreement with Medix Japan, Inc. and Hokushin Medical Co. Ltd. to distribute its Niobe(R) Magnetic Navigation System for cardiac ablations in Japan. The agreement ensures sales and marketing coverage for Stereotaxis in an electrophysiology (EP) market performing approximately 47,000 procedures each year and expected to grow at an annual rate of 10% through 2018. Japan also represents one of the largest medical device markets globally, second to the U.S.
Stereotaxis Reports 2013 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Tue Feb 25, 3:05PM CST
-Announces Distribution Partnership in Japan-
Stereotaxis Up 35.2% Since SmarTrend Uptrend Call (STXS)
Comtex SmarTrend(R) - Tue Feb 25, 10:58AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 35.24% as of today's recent price of $5.68.
Stereotaxis to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014
GlobeNewswire - Wed Feb 19, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2013 fourth quarter and full year ended December 31, 2013 on Tuesday, February 25, 2014 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
Shares of STXS Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 18, 9:39AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 39.76% as of today's recent price of $5.87.
Stereotaxis Appoints William C. Mills III to Chief Executive Officer
GlobeNewswire - Fri Feb 14, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that its board of directors has appointed Chairman William C. Mills III to Chief Executive Officer, effective February 12, 2014. Mr. Mills has been serving as interim CEO since April 2013.
Shares of STXS Up 22.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 11, 9:09AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 22.86% as of today's recent price of $5.16.
5 Stocks Ready to Break Out
at The Street - Fri Jan 17, 12:24PM CST
These stocks are poised to break out and trade higher from current levels.
Stereotaxis to Present New Clinical Evidence, Features of Automated Technologies at Heart Rhythm 2014
GlobeNewswire - Tue May 06, 3:24PM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced several firsts for its eleventh appearance at the annual Heart Rhythm Society (HRS) Scientific Sessions, to be held May 7-10, 2014 in San Francisco, CA. With a central theme of "Efficiency Established; Outcomes Proven; Safety Undoubted," the Company will share new clinical evidence around efficiencies achieved through its Epoch(TM) Solution, showcase a seminal feature of its latest generation user interface and, for the first time, present the value of its Vdrive(TM) Robotic Navigation System to a U.S. audience.
Stereotaxis Reports 2014 First Quarter Financial Results
GlobeNewswire - Tue May 06, 3:24PM CDT
-Records $7 Million in Recurring Revenue, Aided by Sequential Procedure Growth-
Stereotaxis to Report First Quarter 2014 Financial Results on May 6, 2014
GlobeNewswire - Wed Apr 30, 5:42AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 first quarter ended March 31, 2014 on Tuesday, May 6, 2014 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
Stereotaxis Submits 510(k) Application to FDA for Vdrive(TM) with V-Loop(TM) System
GlobeNewswire - Tue Apr 01, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has submitted a 510(k) Premarket Notification with the Food and Drug Administration (FDA) for the Company's Vdrive(TM) Robotic Navigation System with V-Loop(TM) Variable Loop Catheter Manipulator. This submission includes both the single arm system (Vdrive) and the two arm system (Vdrive Duo). If cleared by the FDA, the Vdrive with V-Loop system will be the Company's second Vdrive product to be cleared for use in the U.S. Its Vdrive with V-Sono(TM) Intracardiac Echocardiography Catheter Manipulator received FDA clearance in July 2013 and has been utilized in more than 75 cardiac ablation procedures to date in North America.
Stereotaxis Expands Credit Facility With Silicon Valley Bank to $10 Million
GlobeNewswire - Mon Mar 31, 5:30AM CDT
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into an amended credit agreement with Silicon Valley Bank (SVB) that replaces its existing $3 million revolving facility with a $10 million revolving facility scheduled to mature on March 31, 2015.
20.2% Return Seen to Date on SmarTrend Stereotaxis Call (STXS)
Comtex SmarTrend(R) - Tue Mar 04, 5:21PM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 20.24% as of today's recent price of $5.05.
Nasdaq stocks posting largest percentage decreases
AP - Wed Feb 26, 12:51PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Stereotaxis Signs Distribution Agreement for Niobe(R) Technology in Japan
GlobeNewswire - Tue Feb 25, 3:06PM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has entered into a definitive agreement with Medix Japan, Inc. and Hokushin Medical Co. Ltd. to distribute its Niobe(R) Magnetic Navigation System for cardiac ablations in Japan. The agreement ensures sales and marketing coverage for Stereotaxis in an electrophysiology (EP) market performing approximately 47,000 procedures each year and expected to grow at an annual rate of 10% through 2018. Japan also represents one of the largest medical device markets globally, second to the U.S.
Stereotaxis Reports 2013 Fourth Quarter and Full Year Financial Results
GlobeNewswire - Tue Feb 25, 3:05PM CST
-Announces Distribution Partnership in Japan-
Stereotaxis Up 35.2% Since SmarTrend Uptrend Call (STXS)
Comtex SmarTrend(R) - Tue Feb 25, 10:58AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 35.24% as of today's recent price of $5.68.
Stereotaxis to Report Fourth Quarter and Full Year 2013 Financial Results on February 25, 2014
GlobeNewswire - Wed Feb 19, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2013 fourth quarter and full year ended December 31, 2013 on Tuesday, February 25, 2014 after the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. Eastern Time that day to discuss the Company's results and corporate developments.
Shares of STXS Up 39.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 18, 9:39AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 39.76% as of today's recent price of $5.87.
Stereotaxis Appoints William C. Mills III to Chief Executive Officer
GlobeNewswire - Fri Feb 14, 5:30AM CST
Stereotaxis, Inc. (Nasdaq:STXS) announced today that its board of directors has appointed Chairman William C. Mills III to Chief Executive Officer, effective February 12, 2014. Mr. Mills has been serving as interim CEO since April 2013.
Shares of STXS Up 22.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Feb 11, 9:09AM CST
SmarTrend identified an Uptrend for Stereotaxis (NASDAQ:STXS) on December 23rd, 2013 at $4.20. In approximately 2 months, Stereotaxis has returned 22.86% as of today's recent price of $5.16.
5 Stocks Ready to Break Out
at The Street - Fri Jan 17, 12:24PM CST
These stocks are poised to break out and trade higher from current levels.
